Relationship between rate of infusion and reinforcing strength of oxycodone in humans

Journal of Opioid Management

Volumn 5, Issue 4, 2009, Pages 203-212

  Comer, Sandra D ^a,b   Ashworth, Judy B ^c   Sullivan, Maria A ^a,b   Vosburg, Suzanne K ^a,b   Saccone, Phillip A ^a,b   Foltin, Richard W ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

Abuse deterrent; Abuse liability; Humans; Opiates; Oxycodone; Rate of infusion; Reinforcing effects; Self administration

Indexed keywords

OXYCODONE;

ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG EFFECT; DRUG INFUSION; FEMALE; HEROIN DEPENDENCE; HUMAN; INFUSION RATE; MALE; TASK PERFORMANCE;

EID: 70349221128     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2009.0022     Document Type: Article

References (25)

1. Substance Abuse and Mental Health Services Administration (SAMHSA): Results from the 2007 National Household Survey on Drug Use and Health: National findings, 2008.
2. Manchikanti L, Singh A: Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008; 11 (Opioid Special Issue): S63-S88. (Pubitemid 351682079)
3. Katz N, Fernandez K, Chang A, et al.: Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain. 2008; 24: 528-535.
4. Balster RL, Schuster CR: Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav. 1973; 20: 119-129.
5. Panlilio LV, Goldberg SR, Gilman JP, et al.: Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. Psychopharmacology. 1998; 137: 253-258.
6. Woolverton WL, Wang Z: Relationship between injection duration, transporter occupancy, and reinforcing strength of cocaine. Eur J Pharmacol. 2004; 486: 251-257.
7. Lile JA, Wang Z, Woolverton WL, et al.: The reinforcing efficacy of psychostimulants in rhesus monkeys: The role of pharmacokinetics and pharmacodynamics. J Pharmacol Exp Ther. 2003; 307(1): 356-366. (Pubitemid 37151928)
8. Woolverton WL, Ranaldi R, Wang Z, et al.: Reinforcing strength of a novel dopamine transporter ligand: Pharmacodynamic and pharmacokinetic mechanisms. J Pharmacol Exp Ther. 2002; 303: 211-217. (Pubitemid 35056470)
9. Abreu ME, Bigelow GE, Fleisher L, et al.: Effect of injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology. 2001; 154: 76-84. (Pubitemid 32186518)
10. Nelson RA, Boyd SJ, Ziegelstein RC, et al.: Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend. 2006; 82: 19-24. (Pubitemid 43289100)
11. de Wit H, Bodker B, Ambre J: Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology. 1992; 107(2-3): 352-358.
12. de Wit H, Dudish S, Ambre J: Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology. 1993; 112(2-3): 324-330. (Pubitemid 23278296)
13. Mumford GK, Evans SM, Fleishaker JC, et al.: Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther. 1995; 57: 356-365.
14. Roset PN, Farre M, de la Torre R, et al.: Modulation of rate of onset and intensity of drug effect reduces abuse potential in healthy males. Drug Alcohol Depend. 2001; 64: 285-298. (Pubitemid 32973872)
15. Marsch LA, Bickel WK, Badger GJ, et al.: Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther. 2001; 299: 1056-1065.
16. Farre M, Cami J: Pharmacokinetic considerations in abuse liability evaluation. Br J Addict. 1991; 86: 1601-1606.
17. Comer SD, Sullivan MA, Whittington RA, et al.: Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology. 2008; 33: 1179-1191.
18. Zacny JP, Lichtor SA: Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology. 2008; 196(1): 105-116.
19. Walsh SL, Nuzzo PA, Lofwall MR, et al.: The relative abuse liability of oral oxycodone, hydrocodone, and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008; 98: 191-202.
20. Hays L, Kirsh KL, Passik SD: Seeking drug treatment for Oxycontin abuse: A chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw. 2003; 1(3): 1-6.
21. Comer SD, Collins ED, Fischman MW: Choice between money and intranasal heroin in morphine-maintained humans. Behav Pharmacol. 1997; 8: 667-690.
22. Comer SD, Collins ED, Wilson ST, et al.: Effects of an alternative reinforcer on i.v. heroin self-administration by humans. Eur J Pharmacol. 1998; 345(1): 13-26.
23. Comer SD, Collins ED, MacArthur RB, et al.: Comparison of intranasal and intravenous heroin self-administration by morphine-maintained humans. Psychopharmacology. 1999; 143: 327-338.
24. Comer SD, Sullivan MA, Walker EA: Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther. 2005; 315(3): 1320-1330.
25. Carise D, Leggett Dugosh K, McLellan AT, et al.: Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007; 164: 1750-1756. (Pubitemid 350205353)